Tubize-Fin Cash Flow Conversion Efficiency
Tubize-Fin cash flow conversion efficiency. Based on the latest financial reports, Tubize-Fin (TUB) has a cash flow conversion efficiency ratio of 0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€100.76 Million ≈ $117.80 Million USD) by net assets (€1.99 Billion ≈ $2.32 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tubize-Fin (2004–2025)
Cash flow conversion efficiency of Tubize-Fin from 2004 to 2025. This chart illustrates how Tubize-Fin's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tubize-Fin stock price for real-time trading data and today's change.
Tubize-Fin Cash Flow Conversion Ratio Explained
Tubize-Fin cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tubize-Fin Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tubize-Fin ranked by their cash flow conversion efficiency. Also see Tubize-Fin market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Azek Company Inc
NYSE:AZEK
|
0.032x |
|
Berry Global Group Inc
NYSE:BERY
|
0.063x |
|
MOL NA A ADR REG.S 1/2
F:MOGG
|
0.046x |
|
Companhia Paranaense de Energia - COPEL
NYSE:ELPC
|
0.023x |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
0.047x |
|
ALK-Abelló A/S
CO:ALK-B
|
0.112x |
|
Guangzhou Tinci Materials Technology Co Ltd
SHE:002709
|
0.038x |
|
National Retail Properties Inc
NYSE:NNN
|
0.029x |
Annual Cash Flow Conversion Efficiency for Tubize-Fin (2004–2025)
The table below shows the annual cash flow conversion efficiency of Tubize-Fin from 2004 to 2025. Review TUB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.89 Billion ≈ $2.20 Billion |
€91.84 Million ≈ $107.37 Million |
0.049x | +4432.70% |
| 2024-12-31 | €1.84 Billion ≈ $2.15 Billion |
€-2.07 Million ≈ $-2.42 Million |
-0.001x | +1.28% |
| 2023-12-31 | €1.80 Billion ≈ $2.10 Billion |
€-2.05 Million ≈ $-2.39 Million |
-0.001x | -101.14% |
| 2022-12-31 | €1.75 Billion ≈ $2.05 Billion |
€174.23 Million ≈ $203.69 Million |
0.099x | +27868.38% |
| 2021-12-31 | €3.25 Billion ≈ $3.80 Billion |
€-1.16 Million ≈ $-1.36 Million |
0.000x | +52.23% |
| 2020-12-31 | €2.79 Billion ≈ $3.27 Billion |
€-2.09 Million ≈ $-2.45 Million |
-0.001x | -74.16% |
| 2019-12-31 | €2.66 Billion ≈ $3.11 Billion |
€-1.15 Million ≈ $-1.34 Million |
0.000x | -101.33% |
| 2018-12-31 | €2.34 Billion ≈ $2.74 Billion |
€75.76 Million ≈ $88.57 Million |
0.032x | -6.11% |
| 2017-12-31 | €2.12 Billion ≈ $2.47 Billion |
€72.96 Million ≈ $85.30 Million |
0.034x | -0.28% |
| 2016-12-31 | €1.96 Billion ≈ $2.29 Billion |
€67.70 Million ≈ $79.15 Million |
0.035x | +6.14% |
| 2015-12-31 | €1.95 Billion ≈ $2.28 Billion |
€63.45 Million ≈ $74.18 Million |
0.033x | +8720.77% |
| 2014-12-31 | €1.62 Billion ≈ $1.90 Billion |
€-613.00K ≈ $-716.66K |
0.000x | +28.75% |
| 2013-12-31 | €1.55 Billion ≈ $1.81 Billion |
€-823.00K ≈ $-962.17K |
-0.001x | +43.61% |
| 2012-12-31 | €1.49 Billion ≈ $1.74 Billion |
€-1.40 Million ≈ $-1.64 Million |
-0.001x | -1274.66% |
| 2011-12-31 | €1.55 Billion ≈ $1.81 Billion |
€124.00K ≈ $144.97K |
0.000x | +110.32% |
| 2010-12-31 | €1.44 Billion ≈ $1.69 Billion |
€-1.12 Million ≈ $-1.31 Million |
-0.001x | +91.77% |
| 2009-12-31 | €1.36 Billion ≈ $1.59 Billion |
€-12.79 Million ≈ $-14.96 Million |
-0.009x | -311.75% |
| 2008-12-31 | €1.20 Billion ≈ $1.40 Billion |
€5.32 Million ≈ $6.22 Million |
0.004x | +0.18% |
| 2007-12-31 | €1.26 Billion ≈ $1.47 Billion |
€5.61 Million ≈ $6.55 Million |
0.004x | -98.16% |
| 2006-12-31 | €1.36 Billion ≈ $1.58 Billion |
€327.96 Million ≈ $383.42 Million |
0.242x | +1799.40% |
| 2005-12-31 | €901.39 Million ≈ $1.05 Billion |
€-12.84 Million ≈ $-15.01 Million |
-0.014x | -376.61% |
| 2004-12-31 | €592.56 Million ≈ $692.76 Million |
€3.05 Million ≈ $3.57 Million |
0.005x | -- |
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.